Use the data from the real world and AI to advance research and processing for benign prostate hyperplasia

Benign prostate hyperplasia (BPH) is one of the most common urological conditions affecting men as they age, with almost 50% of men over 50 symptoms. Despite its prevalence, the processing routes remain complex, requiring a nuanced understanding of the progression of the disease, the responses of patients and the treatment of the real world.

Traditional clinical trials provide precious information, but it is often limited and may not fully grasp the various experiences of patients observed in routine clinical environments. This is where real data (RWD) and advanced artificial intelligence technology (AI) play a transformative role.

The power of the real world data in urological research

The real world data – derived from various sources of health care, including electronic health files (DSE), medical allegations and genomics – gives a complete vision of disease trends, treatment results and patient experiences beyond the controlled environment of clinical trials. For HBP, RWD can help companies and clinicians in life sciences understand the effectiveness of the real world of different treatment methods, from drugs to mini-invasive surgical therapies.

To be really useful, the actual data organized must be of high quality, adjusted to use and adapted to its planned use. This allows researchers to better understand the progression of the disease and the results of patients, such as monitoring PSA levels and symptom scores in conditions such as HBP.

By taking advantage of the DSE data identified, companies in the life sciences can discover the trends in the progression of the disease, identify the subpopulations of the patients who are most likely to benefit from specific interventions and refine treatment directives to reflect the experiences of the real world. In addition, the RWD allows longitudinal studies that follow patients’ results over time, providing information on sustainability of treatments and the potential for recurrence of the disease.

AI information: transforming RWD into usable knowledge

Although RWD holds a huge promise, its volume and its complexity require advanced analytical tools to extract significant information, called real world evidence (RWE). AI, in particular automatic learning models, improves the ability to process and analyze large -scale data sets, by identifying models that may not be immediately apparent thanks to traditional analysis.

AI models can normalize and provide a structure to unstructured clinical notes, ensuring the consistency of data interpretation. Natural language treatment techniques, for example, can extract the relevant clinical details from the notes of clinicians, expanding the extent of the data available for the analysis. In addition, the analysis fueled by AI can stratify patients according to the severity of the disease, comorbidities and responses to treatment, ultimately supporting personalized medicine approaches in the management of BPH.

Improvement of research and treatment decision -making

The integration of RWD and AI has important implications for clinical research and patient care. For life sciences and manufacturers of medical devices, access to robust real data sets allows more effective study conceptions, improves post-market monitoring efforts and supports regulatory submissions with RWE. For clinicians, RWD information improved by AI can shed light on shared decision -making, ensuring that treatment recommendations align with the experiences and results of patients in the real world.

In addition, by taking advantage of RWDs identified in an environment protected by privacy, researchers can carry out retrospective analyzes to assess the safety and efficiency of long -term treatment without time and expenditure associated with traditional prospective studies.

A future motivated by RWD and AI

The synergy between RWD and AI is essential to shape the future of urological research and patient care. The ability to exploit real -scale real information allows companies and clinicians in the life sciences to develop more targeted therapies, improve patient results and stimulate innovation based on evidence in the treatment of HBP.

By adopting the power of secure and advanced AI technology and real world data, we can get closer to a more predictive, personalized and impactful health care ecosystem for patients with HBP and beyond.

Photo: Nevarpp, Getty Images

This message appears through the Medcity influencers program. Anyone can publish their point of view on business and innovation in health care on Medcity News through Medcity influencers. Click here to find out how.